Patent · US Active

Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine

US11571471B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Robin Steigerwald · Munich, DE
Markus Kalla · Penzberg, DE

Key dates

Filing date	Jan 4, 2021
Grant date	Feb 7, 2023
Priority date	—
Expiry date	Jan 4, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/36134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.